<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05053087</url>
  </required_header>
  <id_info>
    <org_study_id>21-000974</org_study_id>
    <nct_id>NCT05053087</nct_id>
  </id_info>
  <brief_title>A Study to Compare the Effectiveness of Adductor Canal Pain Catheters Following Total Knee Arthroplasty</brief_title>
  <official_title>A Three-Arm, Double-Blinded, Randomized Controlled Trial Comparing the Efficacy of Adductor Canal Pain Catheters Following Total Knee Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to study how well the adductor canal pain catheters works&#xD;
      after a total knee arthroplasty or replacement of the knee joint. The catheter works by using&#xD;
      either an intermittent bolus injection to provide a large dose of medication or continuous&#xD;
      infusion of pain medicine, ropivacaine 0.2%, compared to a single-shot adductor canal block.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 15, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A Three-Arm, Double-Blinded, Randomized Controlled Trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>This will be a double-blinded study. Computer randomization will be used for patient grouping and the research pharmacy will dispense the medication to the anesthesia team, who will set the adductor catheter dosing based upon randomization. The surgical team and patient will remain blinded to the medication and dosing regimen.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Post-operative pain levels</measure>
    <time_frame>14 days post-operatively</time_frame>
    <description>Measured using a visual analogue scale (VAS) where subject places a mark on a horizontal line to rate the intensity of their pain at the time between no pain and worst pain imaginable.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Amount of medication administered</measure>
    <time_frame>60 days, or until discontinuation of narcotic medication (whichever is later)</time_frame>
    <description>Amount of medication administered via the patient-controlled function on the adductor catheter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of narcotic used</measure>
    <time_frame>60 days, or until discontinuation of narcotic medication (whichever is later)</time_frame>
    <description>Number of days narcotic use is required</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>Ropivacaine group with bolus infusions</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will have a catheter placed in the Post Anesthesia Care Unit following clinically indicated surgery with 0.2% ropivacaine dispersed in pulsed intermittent bolus.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ropivacaine group with continuous infusions</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will have a catheter placed in the Post Anesthesia Care Unit following clinically indicated surgery with 0.2% ropivacaine dispersed in a continuous infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single shot adductor canal block group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will have a catheter placed in the Post Anesthesia Care Unit following clinically indicated surgery with saline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine Continuous Infusion</intervention_name>
    <description>0.2% continuous infusion 6mL/hr</description>
    <arm_group_label>Ropivacaine group with continuous infusions</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine Intermittent Bolus</intervention_name>
    <description>0.2% intermittent bolus infusion 8mL every 2 hours</description>
    <arm_group_label>Ropivacaine group with bolus infusions</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline filled catheter</description>
    <arm_group_label>Single shot adductor canal block group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 and ≤ 90 years.&#xD;
&#xD;
          -  Willing to participate in the study and competent to provide informed consent.&#xD;
&#xD;
          -  Willing to comply with protocol procedures.&#xD;
&#xD;
          -  Has an underlying diagnosis of osteoarthritis indicated for a total knee arthroplasty.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The patient must not have taken any narcotic medications (schedule II) during the 3&#xD;
             months leading up to the surgery.&#xD;
&#xD;
          -  The patient must not be allergic or intolerant to a medication used in the multimodal&#xD;
             pain pathway.&#xD;
&#xD;
          -  Revision knee arthroplasty.&#xD;
&#xD;
          -  Uncontrolled diabetes with A1C &gt; 8.0%.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin Wilke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arjana Haliliovic</last_name>
    <phone>(904) 953-8894</phone>
    <email>halilovic.arjana@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lori Chase, MS</last_name>
    <phone>(904) 953-8894</phone>
    <email>chase.lori@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic in Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 13, 2021</study_first_submitted>
  <study_first_submitted_qc>September 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 22, 2021</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Benjamin K. Wilke</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

